摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3'-amino-2-bromoacetophenone hydrobromide | 15473-81-1

中文名称
——
中文别名
——
英文名称
3'-amino-2-bromoacetophenone hydrobromide
英文别名
3-amino-phenacyl bromide hydrobromide;1-(3-aminophenyl)-2-bromoethanone;hydrobromide
3'-amino-2-bromoacetophenone hydrobromide化学式
CAS
15473-81-1
化学式
BrH*C8H8BrNO
mdl
——
分子量
294.974
InChiKey
PGBARHRJKVWGFH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.42
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    43.1
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    喹诺酮类抗菌药。1. 7-(2-取代的4-噻唑基和噻唑烷基)喹诺酮
    摘要:
    合成了一系列的7-(2-取代的4-噻唑基和噻唑烷基)-1-乙基-1,4-二氢-4-氧代喹啉-3-羧酸及其6-氟类似物。汉茨法用于制备噻唑基喹诺酮。通过将相应的噻唑基类似物季铵化,然后用水溶液中的硼氢化钠还原获得的噻唑鎓盐,来合成噻唑烷二基喹诺酮。在体外测试抗菌活性。大多数化合物对革兰氏阴性菌无活性,但其中一些对革兰氏阳性菌和分枝杆菌显示出良好的活性。在喹诺酮类抗菌剂中很少发现这种活性模式。
    DOI:
    10.1002/jhet.5570280323
  • 作为产物:
    描述:
    间氨基苯乙酮乙酸酐 作用下, 以 氯仿 为溶剂, 反应 48.5h, 生成 3'-amino-2-bromoacetophenone hydrobromide
    参考文献:
    名称:
    喹诺酮类抗菌药。1. 7-(2-取代的4-噻唑基和噻唑烷基)喹诺酮
    摘要:
    合成了一系列的7-(2-取代的4-噻唑基和噻唑烷基)-1-乙基-1,4-二氢-4-氧代喹啉-3-羧酸及其6-氟类似物。汉茨法用于制备噻唑基喹诺酮。通过将相应的噻唑基类似物季铵化,然后用水溶液中的硼氢化钠还原获得的噻唑鎓盐,来合成噻唑烷二基喹诺酮。在体外测试抗菌活性。大多数化合物对革兰氏阴性菌无活性,但其中一些对革兰氏阳性菌和分枝杆菌显示出良好的活性。在喹诺酮类抗菌剂中很少发现这种活性模式。
    DOI:
    10.1002/jhet.5570280323
点击查看最新优质反应信息

文献信息

  • Substituted heterocyclyl-phenylformamidines and salts thereof
    申请人:Istituto de Angeli S.p.A.
    公开号:US04699915A1
    公开(公告)日:1987-10-13
    Compounds of the formula ##STR1## wherein R is hydrogen or methyl; R.sub.1 is straight or branched alkyl of 1 to 6 carbon atoms, hydroxy(alkyl of 1 to 6 carbon atoms), mono- or di-(alkoxy of 1 to 6 carbon atoms)(alkyl of 1 to 6 carbon atoms), (alkyl of 1 to 6 cabon atoms)thio(alkyl of 1 to 6 carbon atoms), cyano(alkyl of 1 to 6 carbon atoms), alkenyl, alkynyl, or cycloalkyl; R.sub.2 is hydrogen, alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms or halogen; and X is pyrazol-3-yl, 1,2,4-triazol-3-yl, pyridin-2-yl, pyridin-3-yl, thiazol-4-yl, 2-methyl-thiazol-4-yl or 2-methylamino-thiazol-4-yl; tautomers thereof, and non-toxic, pharmacologiically acceptable acid addition salts thereof. The compounds as well as their salts are useful as antiulcerogenics and gastric acid secretion inhibitors.
    式##STR1##中的化合物,其中R是氢或甲基;R.sub.1是1至6个碳原子的直链或支链烷基,羟基(1至6个碳原子的烷基),单或双(1至6个碳原子的烷氧基)(1至6个碳原子的烷基),(1至6个碳原子的烷基)硫(1至6个碳原子的烷基),氰基(1至6个碳原子的烷基),烯基,炔基或环烷基;R.sub.2是氢,1至3个碳原子的烷基,1至3个碳原子的烷氧基或卤素;X是吡唑-3-基,1,2,4-三唑-3-基,吡啶-2-基,吡啶-3-基,噻唑-4-基,2-甲基噻唑-4-基或2-甲氨基噻唑-4-基;它们的互变异构体,以及非毒性、药理学上可接受的酸盐。这些化合物及其盐可用作抗溃疡剂和胃酸分泌抑制剂。
  • Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
    申请人:——
    公开号:US20020198205A1
    公开(公告)日:2002-12-26
    The present invention relates to substituted xanthines of general formula 1 wherein R 1 to R 4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    本发明涉及一般式1的取代黄嘌呤,其中R1至R4如权利要求1中定义,其互变异构体和立体异构体,其混合物,其前药和其盐,具有有价值的药理特性,特别是对酶二肽基肽酶-IV(DPP-IV)活性的抑制作用。
  • Xanthine derivatives,production and use thereof as medicament
    申请人:——
    公开号:US20040077645A1
    公开(公告)日:2004-04-22
    The present invention relates to substituted xanthines of general formula 1 wherein R 1 to R 4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    本发明涉及一般式1的取代黄嘌呤,其中R1至R4如权利要求1所定义,其互变异构体和立体异构体,混合物,前药和盐具有有价值的药理学性质,特别是对酶二肽基肽酶IV(DPP-IV)的抑制作用。
  • XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
    申请人:Himmelsbach Frank
    公开号:US20060247226A1
    公开(公告)日:2006-11-02
    The present invention relates to substituted xanthines of general formula wherein R 1 to R 4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    本发明涉及一般式为的取代黄嘌呤,其中R1至R4的定义如权利要求1所述,其互变异构体和立体异构体,混合物,前药和盐具有有价值的药理学性质,特别是对酶二肽基肽酶-IV(DPP-IV)的抑制作用。
  • Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
    申请人:HIMMELSBACH Frank
    公开号:US20110144095A1
    公开(公告)日:2011-06-16
    The present invention relates to substituted xanthines of general formula wherein R 1 to R 4 are as defined herein, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    本发明涉及一般式为的取代黄嘌呤,其中R1至R4的定义如本文所述,其互变异构体和立体异构体,混合物,前药和盐具有有价值的药理学特性,特别是对酶二肽基肽酶-IV(DPP-IV)的抑制作用。
查看更多